Tiziano Barbui

Title: Tiziano Barbui: Innovator in Myeloproliferative Syndromes Treatment

Introduction

Tiziano Barbui is a notable inventor based in Bergamo, Italy. He has made significant contributions to the field of medicine, particularly in the treatment of Philadelphia-negative myeloproliferative syndromes. His innovative approach has the potential to improve patient outcomes in this challenging area of healthcare.

Latest Patents

Tiziano Barbui holds a patent titled "Use of histone deacetylase inhibitors for the care of Philadelphia-negative myeloproliferative syndromes." This patent describes a method of treating patients suffering from these syndromes by administering diethyl-[6-(4-hydroxycarbamoyl-phenylcarbamoyloxymethyl)-naphthalen-2-yl-methyl]-ammonium chloride, or other pharmaceutically acceptable salts and/or solvates, in a daily dosage amount ranging from 10 to 150 mg per patient. This innovative treatment method represents a significant advancement in the management of these complex conditions.

Career Highlights

Tiziano Barbui has dedicated his career to research and development in the pharmaceutical industry. He is currently associated with Italfarmaco Spa, where he continues to work on innovative solutions for various medical challenges. His expertise and commitment to advancing medical science have earned him recognition in his field.

Collaborations

Tiziano Barbui collaborates with esteemed colleagues, including Tiziano Oldoni and Paolo Mascagni. These partnerships enhance the research and development efforts at Italfarmaco Spa, fostering an environment of innovation and discovery.

Conclusion

Tiziano Barbui's contributions to the treatment of Philadelphia-negative myeloproliferative syndromes highlight his role as a leading inventor in the pharmaceutical industry. His innovative patent and collaborative efforts demonstrate a commitment to improving patient care and advancing medical science.